Trends in high-dose opioid prescribing in Canada

Canadian Family Physician

Volumn 60, Issue 9, 2014, Pages 826-832

  Gomes, Tara ^a,b,c   Mamdani, Muhammad M ^a,b,c   Paterson, J Michael ^a,d   Dhalla, Irfan A ^a,b,c   Juurlink, David N ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ANALGESIA; CANADA; CLASSIFICATION; CLINICAL PRACTICE; DOSE RESPONSE; HUMAN; MEDICATION THERAPY MANAGEMENT; NEEDS ASSESSMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA; TRENDS;

ANALGESICS, OPIOID; CANADA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEDICATION THERAPY MANAGEMENT; NEEDS ASSESSMENT; PAIN MANAGEMENT; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84907284599     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. International Narcotics Control Board. Opioid consumption motion chart. Madison, WI: Board of Regents of the University of Wisconsin System; 2012. Available from: http://ppsg-production.heroku.com/chart. Accessed 2014 Jul 28
2. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009;181(12):891-6
3. Boudreau D, Von KM, Rutter CM, Saunders K, Ray GT, Sullivan MD, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009;18(12):1166-75
4. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006;31(6):506-11
5. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med 2011;5(1):e13-22
6. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10(2):147-59
7. Purdue Pharma. OxyContin [product monograph]. Pickering, ON: Purdue Pharma; 2009
8. Cherny NI, Por tenoy RK. Cancer pain management. Current strategy. Cancer 1993;72(11 Suppl):3393-415
9. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 2012;23(Suppl 7):vii139-54
10. Agency Medical Directors' Group. Interagency guideline on opioid dosing for chronic non-cancer pain: an educational pilot to improve care and safety with opioid treatment. Olympia, WA: Washington State Agency Medical Directors' Group; 2 007
11. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2): 113-30
12. National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Hamilton, ON: McMaster University; 2010. Available from: http://nationalpaincentre.mc master.ca/opioid. Accessed 2014 Jul 28
13. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152(2):85-92
14. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011;305( 13):1315-21
15. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011;171(7):686-91
16. Gomes T, Redelmeier DA, Juurlink DN, Dhalla IA, Camacho X, Mamdani MM. Opioid dose and risk of road trauma in Canada: a population-based study. JAMA Intern Med 2013;173(3):196-201
17. Miller M, Sturmer T, Azrael D, Levin R, Solomon DH. Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc 2011;59(3):430-8.
18. Nova Scotia Prescription Monitoring Program [website] Halifax NS Prescription Monitoring Board, 2013, Available from, www.nspmp.ca. Accessed 2014 Jul 28.
19. The Prescription Review Program. Regina, SK: Government of Saskatchewan; 2012. Available from: http://formulary.drugplan.health.gov.sk.ca/PDFs/ThePrescriptionReviewProgram.pdf. Accessed 2014 Jul 28
20. PharmaNet [website]. Vancouver, BC: Government of British Columbia; 2007. Available from: www.health.gov.bc.ca/pharmacare/pharmanet/netindex. html. Accessed 2014 Jul 28
21. College of Physicians and Surgeons of Alberta. Triplicate Prescription Program. Edmonton, AB: College of Physicians and Surgeons of Alberta ; 2012. Available from: www.cpsa.ab.ca/Services/Triplicate-Prescription- Program/TPP-Overview.aspx. Accessed 2014 Jul 28
22. OxyContin Task Force. OxyContin Task Force final report. St John's, NL: Government of Newfoundland and Labrador; 2004
23. Fischer B, Jones W, Krahn M, Rehm J. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol Drug Saf 2011;20(12):1269-77
24. Gomes T, Paterson JM, Juurlink DN, Dhalla I A, Mamdani M. Reformulation of controlled-release oxycodone and pharmacy dispensing patterns near the US-Canada border. Open Med 2012;6(4):e141-5
25. IMS Audit Training [website]. IMS Health; 2013. Available from: http://canadaelearning.imshealth.com/cs/index.html. Accessed 2014 Jul 28
26. Statistics Canada. Population and dwelling counts, for Canada, provinces and territories, and census subdivisions (municipalities), 2006 and 2001 censuses. Ottawa, ON: Statistics Canada; 2006
27. Morden NE, Zerzan JT, Rue TC, Heagerty PJ, Roughead EE, Soumerai SB, et al. Medicaid prior authorization and controlled-releas e oxycodone. Med Care 2008;46(6):573-80
28. Lu CY, Law MR, Soumerai SB, Graves AJ, LeCates RF, Zhang F, et al. Impact of prior authorization on the use and costs of lipid-lowering me dications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther 2011;33(1):135-44
29. Ramage-Morin PL, Gilmour H. Chronic pain at ages 12 to 44. Health Rep 2010;21(4):53-61
30. Van Den Kerkhof EG, Hopman WM, Towheed TE, Anastassiades TP, Goldstein DH. The impact of sampling and measurement on the prevalence of self-reported pain in Canada. Pain Res Manag 2003;8(3):157-63
31. Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Res Manag 2011;16(6):445-50
32. . Lexchin J, Kohler JC. The danger of imperfect regulation: OxyContin use in the United States and Canada. Int J Risk Saf Med 2011;23(4):233-40
33. Whelan E, Asbridge M, Haydt S. Representations of OxyContin in North American newspapers and medical journals. Pain Res Manag 2011;16(4):252-8